Pay in 4 interest-free payments of $7.19 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
2025 guidance: USD 58-61B Key Peptide Products: Tirzepatide (Mounjaro for T2D, Zepbound for obesity/OSA), dulaglutide (Trulicity), insulin lispro (Humalog), retatrutide GLP-1/GIP/glucagon triple agonist (Phase 3 pipeline) Therapeutic Segments: Diabetes & Obesity (Incretin)
Eliminate fruit juice, soda, and high-fructose corn syrup
The collection and use of clinical samples were in accordance with research ethics board approval from the Sixth Affiliated Hospital of Sun Yat-sen University Review Board
This intensive approach suits short-term focused treatment phases
US$ 27.23
US$ 24.33
US$ 23.33
US$ 21.07
US$ 29.01
US$ 22.98
US$ 21.61
US$ 27.69
